Who are Inpefa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Apleway, Farxiga, Suglat, Invokana, Jardiance, Brenzavvy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sotagliflozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Inpefa — Competitive Intelligence Brief

Inpefa (SOTAGLIFLOZIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-Glucose Cotransporter 2 Inhibitor [EPC]. Area: Metabolic.

marketed Sodium-Glucose Cotransporter 2 Inhibitor [EPC] Sodium/glucose cotransporter 2 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Inpefa (SOTAGLIFLOZIN) — Lexicon Pharms Inc. Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inpefa TARGET	SOTAGLIFLOZIN	Lexicon Pharms Inc	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	Sodium/glucose cotransporter 2	2023-01-01
Apleway	TOFOGLIFLOZIN		marketed		Sodium/glucose cotransporter 2	2014-01-01
Farxiga	DAPAGLIFLOZIN	AstraZeneca	marketed	Sodium-Glucose Cotransporter 2 Inhibitor	Sodium/glucose cotransporter 2	2014-01-01
Suglat	IPRAGLIFLOZIN		marketed		Sodium/glucose cotransporter 2	2014-01-01
Invokana	CANAGLIFLOZIN	Johnson & Johnson	marketed	Sodium-Glucose Cotransporter 2 Inhibitor	Sodium/glucose cotransporter 2	2013-01-01
Jardiance	Jardiance	University of Louisville	marketed		Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2
Brenzavvy	BEXAGLIFLOZIN	Theracosbio	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01

Recent regulatory actions (last 90 days)

2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-Glucose Cotransporter 2 Inhibitor [EPC] class)

· 1 drug in this class
AJANTA PHARMA LTD · 1 drug in this class
AstraZeneca · 1 drug in this class
Boehringer Ingelheim · 1 drug in this class
Lexicon Pharms Inc · 1 drug in this class
Theracosbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inpefa — Competitive Intelligence Brief. https://druglandscape.com/ci/sotagliflozin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab